REGENERON PHARMACEUTICALS, INC. v. MYLAN PHARMACEUTICALS INC. , No. 24-1402 (Fed. Cir. 2024)
Annotate this Case
Download PDF
Case: 24-1402 Document: 26 Page: 1 Filed: 04/12/2024 NOTE: This order is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ REGENERON PHARMACEUTICALS, INC., Plaintiff-Appellant v. MYLAN PHARMACEUTICALS INC., BIOCON BIOLOGICS INC., Defendants-Cross-Appellants AMGEN USA, INC., Defendant ______________________ 2024-1402, 2024-1405 ______________________ Appeals from the United States District Court for the Northern District of West Virginia in No. 1:22-cv-00061TSK-JPM, Chief Judge Thomas S. Kleeh. ______________________ Before CHEN, LINN, and HUGHES, Circuit Judges. PER CURIAM. ORDER Following this court’s February 22, 2024 show cause order, the parties agree that the court lacks jurisdiction over both the appeal and cross-appeal from the district court’s December 27, 2023 decision resolving fewer than all Case: 24-1402 2 Document: 26 Page: 2 Filed: 04/12/2024 REGENERON PHARMACEUTICALS, INC. v. MYLAN PHARMACEUTICALS INC. claims at issue. Under the circumstances, we agree and conclude that dismissal is appropriate. Accordingly, IT IS ORDERED THAT: (1) Appeal Nos. 2024-1402 and 2024-1405 are dismissed. (2) Each party shall bear its own costs. FOR THE COURT April 12, 2024 Date ISSUED AS A MANDATE: April 12, 2024
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
